Oxandrolone
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Oxandrolone: From Anabolic Steroid Therapy to Breast Fibrocystic Disease
One-Sentence Summary
Oxandrolone is a synthetic anabolic androgen; the evidence pack does not contain a documented original indication, and the drug currently holds no UK marketing authorisation. The TxGNN model predicts a possible link to Breast Fibrocystic Disease, but this is based purely on knowledge-graph inference — no clinical trials and no published literature currently support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally documented — no UK licence exists and the evidence pack contains no approved indication text |
| Predicted New Indication | Breast Fibrocystic Disease |
| TxGNN Prediction Score | 99.23% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Oxandrolone is not currently available in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, Oxandrolone is a synthetic anabolic androgen with weak androgenic activity. Mechanistically, other androgens such as danazol have historically been used to suppress oestrogen-driven breast tissue proliferation, which is the presumed rationale behind the TxGNN link to breast fibrocystic disease — but this is an analogy drawn from the drug class, not direct evidence for Oxandrolone itself.
Because no formally documented original indication is available for this drug, the relationship between prior clinical use and the predicted new indication cannot be properly assessed. Long-term androgen exposure carries recognised virilisation risks, and the risk–benefit balance for a benign, non-life-threatening condition such as fibrocystic breast disease is therefore questionable on mechanistic grounds alone.
Overall, this prediction should be regarded as a hypothesis generated purely by the knowledge graph. It has not been corroborated by any trial, case series, or mechanistic study, and the underlying MOA and safety data needed to properly evaluate plausibility are themselves missing.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Oxandrolone currently holds no UK marketing authorisation (0 licences on record); market status is recorded as Not marketed. No product name, dosage form, or approved indication text is therefore available.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications, and drug–drug interaction data for Oxandrolone are currently unavailable and are flagged as a Blocking data gap — this must be resolved before any initial safety screening (S1) can proceed.
Other TxGNN-Predicted Indications
Three further candidates were generated for Oxandrolone in this run, all at evidence level L5 with a Hold recommendation and no supporting trials or literature:
| Rank | Predicted Indication | TxGNN Score | Mechanistic Rationale (summary) |
|---|---|---|---|
| 2 | Pituitary hormone deficiency from vascular origin | 99.23% | Weak — Oxandrolone does not act on the hypothalamic–pituitary axis; possibly a false-positive graph association |
| 3 | Hypogonadotropic hypogonadism–frontoparietal alopecia syndrome | 99.21% | Theoretical — weak androgen-receptor activation plausible for growth promotion in this rare genetic syndrome, but no direct evidence |
| 4 | Non-acquired combined pituitary hormone deficiencies (without extra-pituitary malformation) | 99.08% | Most mechanistically plausible of the four — Oxandrolone has precedent as a growth-hormone adjunct in short-stature/growth-failure children, but unverified for this specific indication |
Conclusion and Next Steps
Decision: Hold
Rationale: This is a model-only prediction (L5) with no clinical trials, no literature, and no verified mechanism of action. Critical SmPC-level safety data (warnings/contraindications) is also missing and is classified as a Blocking gap, meaning the candidate cannot yet enter formal safety screening.
To proceed, the following is needed:
- SmPC-equivalent warnings and contraindications for Oxandrolone (Blocking — required before S1 safety review)
- Confirmed mechanism of action data
- Primary evidence (trials, case reports, or mechanistic studies) directly linking Oxandrolone to breast fibrocystic disease or any of the other three predicted indications
- Assessment of the licensing pathway required, given Oxandrolone’s current unlicensed status in the UK
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.